NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies | Biotech Hunter

Enrollment

345

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

August 31, 2026

Study Completion Date

February 28, 2028

Conditions

Ovarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) CancerHead and Neck Squamous Cell CarcinomaMetastatic or Unresectable MelanomaNon-small Cell Lung Cancer (NSCLC)Metastatic Castration-resistant Prostate Cancer (mCRPC)Malignant Pleural Mesothelioma (MPM)Triple Negative Breast Cancer (TNBC)Metastatic Urothelial CarcinomaCervical CancerDiffuse Large B Cell Lymphoma (DLBCL)Richter TransformationMicrosatellite Stable Colorectal Carcinoma

Interventions

DRUG

NX-1607

Oral NX-1607

DRUG

Paclitaxel

Paclitaxel IV

Trial Locations (17)

22908

RECRUITING

University of Virginia, Charlottesville

27599

RECRUITING

University of North Carolina, Chapel Hill

60637

RECRUITING

University of Chicago, Chicago

73104

RECRUITING

University of Oklahoma, Oklahoma City

77030

RECRUITING

MD Anderson Cancer Center, Houston

80045

RECRUITING

University of Colorado School of Medicine, Aurora

90007

RECRUITING

University of Southern California, Los Angeles

91010

COMPLETED

City of Hope, Duarte

94158

RECRUITING

University of California, San Francisco, San Francisco

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

SM2 5PT

RECRUITING

Royal Marsden Hospital NHS Foundation Trust, Sutton

CB2 0QQ

RECRUITING

Addenbrookes Cambridge University Hospital, Cambridge

G12 0YN

RECRUITING

Beatson West of Scotland Cancer Centre, Glasgow

W1G 6AD

RECRUITING

Sarah Cannon Research Institute, London

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

NE7 7DN

RECRUITING

Northern Centre for Cancer Care, Newcastle

OX3 7LE

COMPLETED

Churchill Hospital, Oxford